Member Info for Laura2022

Does the chart mean it will move upwards from the grey box ?

I assume the chart shows good movement soon ?

Thanks

DDR is mentioned quite a few times on PYC and also as u say on this article

Thankyou Trench

See my previous reply

The merger is hapoening as per the details posted on VAL and via RNS which I qssime you've read

Trial overview

DETERMINE is a multi-drug, precision medicine trial for adults, teenagers and children with rare cancers. DETERMINE is a trial open in UK.

This trial will explore whether treatments approved for use in some cancer types can target identifiable genetic alterations in other types. And provide new treatments options for those who might not have any left.

Drugs which show promising results will be accelerated for Cancer Drug Fund (CDF) assessment and NHS approval.

This project seems to fit PYC technologies and mentions CRUK and fast tracking drugs , plus matching drugs to disease.

Determine has been set up to find if drugs that are already prescribed by doctors for more common types of cancer could benefit patients with rare cancers for which they have not been licensed.

The study is led by Manchester University, sponsored by the Cancer Research UK Centre for Drug Development, and involves several other leading medical centres in the UK. The ultimate aim is to match old drugs for new cancers.

The Christie NHS Foundation Trust in Manchester where Lisa Park’s rare cancer was treated. Photograph: John B Hewitt/Shutterstock

The crucial point is that, with recent advances in DNA analysis, scientists have discovered some very rare tumours possess abnormalities that could make them susceptible to treatments developed for common cancers. “We will be able to fast-track the approval of any promising drugs, opening the door to treatments for patients who have historically been left with limited options,” said Iain Foulkes, the executive director of research and innovation at Cancer Research UK.

This about UK companies matching drugs to rare cancers

https://www.theguardian.com/science/2023/oct/14/patients-with-rare-cancers-given-hope-by-uk-led-drug-match-trial

This is taken from the PYC annual report ( I have highlighted in capitals)

"During the year, the Company's US partner DoseMeRx announced that it had been divested by its owner Tabula Rasa Healthcare (TRHC) and acquired by a private equity company. Since then, the Company has re-established contact with DoseMeRx and DISCUSSIONS are ONGOING around how the Company's tool might be USED IN THE US".

Very many thanks for the links and information

Sounds very exciting

As for Dosemerx that is very encouraging that they were in attendance too,PYC have consistently highlighted that they are still in CUŔRENT discussions and its good that Dosem were tlaking about their precision tool at the conference

Ankyra Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ANK-101 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

ANK-101 is a novel first-in-class anchored IL-12 immunotherapy designed for limited intratumoral delivery to increase immune cell infiltration into tumors, with potential to improve outcomes of patients treated with immune checkpoint inhibitors

CAMBRIDGE, Mass. – October 4, 2023, (BUSINESSWIRE) – Ankyra Therapeutics, a clinical biotechnology company developing a new form of local immunotherapy termed “anchored immunotherapy,” today announced a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the US and Canada) to evaluate ANK-101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) following the completion of a first-in-human phase I study of ANK-101 alone in patients with advanced solid tumors

Thanks Debull

Can u copy full text as the link is removed

Apparently you need 20+ days as a discussion poster for LSE to let u post links

I found the same problem last year

With the American clients and audience do people think American investors will start to buy PYC shares or can they not access UK companies ?

 program attracts 1,200-1,500 academics, scientists, and pharmaceutical industry representatives from across the globe to discuss innovations in drug development, target selection, the impact of new discoveries in cellular and molecular biology, and early clinical trials

Looks like there is not much shares to buy MSUK ?

Looks interesting thanks

Looks like it's 1 78p/1 8p to buy now

Any shares at 1.7p

Bid to come today for their assets?

See RNS

I think you are right maverick and Latin

2 of them just appeared from yesterday

, a potential sale of the shares in the subsidiaries and/or a sale of the business and assets of the subsidiaries ("the Process"). 

 

The Board can also update the market that the Process underway has resulted in a number of different parties declaring their interest at this time and the Board and its advisors will continue to engage with these parties in the coming days

Directors buying at 12.89p in August too